substance misuse

Example templates of proposed submission and assessment arrangements for young people's commissioners to use in their planning processes. Includes: 1. Young people’s specialist substance misuse treatment planning 2009/10: Guidance notes on planning processes for strategic partnerships. 2. Young people’s specialist substance misuse treatment plan 2009/10. 3.. Planning grids. 4. Expenditure profile.

Document offering guidance on good practice around identifying the needs of young people requiring specialist substance misuse treatment.

Case study from East Sussex showing how a multi-agency approach to the issue of substance misuse among young people was developed and offering implementation tips to others on the best ways to achieve the same approach.

The National Treatment Agency for Substance Misuse (NTA) aims to increase the availability, capacity and effectiveness of treatment for drug misuse in England. This site includes details of the NTA's work programme, as well as publications and guidance for those in the drug treatment sector.

Resource containing a set of tools and resources to help partnerships concerned with the health of looked after children to carry out audits of services, formulate action plans and gather evidence of their progress.

This paper describes the system by which the Registrar General for Scotland collects information on drug-related deaths in Scotland and presents selected statistical information covering the period 1996 to 2001.

This blog is written by David Clark, director of Wired In, an organisation that empowers individuals, families and communities to tackle substance use problems, encouraging and enabling people to find their path to recovery. The blog contains links to films and background briefings relevant to recovery.

This resource provides information and advice on drugs in Scotland for anyone who wants to learn more about drugs including parents and health professionals.

BioSocieties is committed to the scholarly exploration of the crucial social, ethical and policy implications of developments in the life sciences and biomedicine. It provides a crucial forum where the most rigorous social research and critical analysis of these issues can intersect with the work of leading scientists, social researchers, clinicians, regulators and other stakeholders.